Bitcoin futures open interest rose 42.2% in November, and ethereum futures open interest rose 72.7%
According to data disclosed by TheBlock analyst Lars, the open interest in bitcoin futures rose 42.2% in November, and the open interest in ethereum futures rose 72.7%; in terms of futures turnover, bitcoin futures traded up 69.2% % to $2.1 trillion in November, and ethereum futures traded up 92.8%. The open interest in bitcoin futures at the ChiNext increased by 61.4% to $20.1 billion (reaching an all-time high), the average daily avg volume (DAVG volume) rose 86.9% to about $9.8 billion, and ethereum futures average monthly trading volume grew to $940 billion, a rise of 92.8%. In terms of cryptocurrency options, bitcoin options open interest rose 53.2% in November, while ethereum options open interest rose 84.2 In addition, in terms of bitcoin and ethereum options turnover, bitcoin's monthly options volume reached $110.9 billion, up 105.3%, and ethereum options volume was $21.9 billion, a rise of 115.5%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BNP Paribas gives Microsoft (MSFT.US) a "Buy" rating: Azure price increases will be gradually implemented after contract renewals, and a deal with SpaceX may be announced soon.
BNP Paribas has rated Microsoft as "Buy" with a target price of $549.
Iranian President will head to New York for UN meeting
"Big Short" Burry opens a position in QXO (QXO.US), betting on building products integration and undervaluation; stock price rises over 7%
Investor Michael Burry disclosed that he has purchased common and preferred shares of QXO (QXO.US), a building products company, citing its integration strategy and the currently depressed stock price. The stock surged 7.2% on Monday.
700,000 new elderly patients join, Eli Lilly (LLY.US) dominates 70%: The first Medicare weight loss drug coverage report released
Dave Ricks, CEO of Eli Lilly (LLY.US), said in an interview on Monday that since Medicare began coverage for obesity drugs in July, 700,000 new elderly patients have started using GLP-1 medications.